Vaccination for Patients with Hematologic Diseases
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 31 August 2026
Special Issue Editor
Interests: chronic myeloproliferative neoplasms; immune thrombocytopenia; evidence-based medicine; artificial intelligence; decision analysis; health technology assessment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Patients with blood disorders often demonstrate a suboptimal response to viral and bacterial infections. Therefore, active or passive immune prophylaxis is essential in specific subgroups to improve infection outcomes. The most effective strategy for preventing adverse outcomes related to infections depends on various factors, including host-related, disease-related, therapy-related, and context-related considerations, as well as the availability of specific vaccines. We are pleased to invite you to contribute to this Special Issue, which will focus on active and passive immune prophylaxis in patients with blood malignancies or non-neoplastic blood disorders.
This Special Issue will explore strategies to selectively enhance patients' immune responses to specific infections and the broad clinical implications of effective prevention in those undergoing complex treatment sequences. Original research articles and reviews are welcome. Areas of interest include the management of vaccination in patients eligible for CAR T-cell therapies, the current management of active and passive immune prophylaxis for SARS-CoV-2, and newly introduced RSV vaccines.
Thank you for considering this opportunity to share your insights and research.
Dr. Monia Marchetti
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine
- SARS-CoV-2
- influenza
- leukemia
- lymphoma
- myeloma
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
